img

ESC 2018

Here you will find the highlights of the ESC 2018, held on August 25-29 in the city of Múnich, Gemany.

MITRA FR: el testeo del MitraClip en las insuficiencias mitrales funcionales

ESC 2018 | MITRA FR: Testing MitraClip for Secondary Mitral Regurgitation
Courtesy of Dr. Carlos Fava. In secondary mitral regurgitation, mitral-valve leaflets and chordae are structurally normal and mitral regurgitation results from alterations in left ...

ESC 2018 | FRANCE-TAVI: Atrial Fibrillation and Anticoagulation Associated to Mortality in TAVR
Some of the many ongoing randomized studies including patients with atrial fibrillation (AF) might finally answer the question on the best antithrombotic scheme post TAVR. According to this ...

ART: desilusión de la revascularización con doble mamaria a 10 años de seguimiento

ESC 2018 | ART: Disappointment with Bilateral Internal-Thoracic Artery Grafts After a 10-Year Follow-Up
Published 5-year results had been neutral for bilateral vs. single internal-thoracic artery grafts, but, at the time, surgeons argued that the time period analyzed was not enough and that a ...

CULPRIT-SHOCK: los resultados a 1 año continúan soportando tratar solo la arteria culpable

ESC 2018 | CULPRIT-SHOCK: 1-Year Results Continue to Support Treatment of the Culprit Artery Only
Increases in the rates of revascularization and heart failure do not justify the early mortality advantage shown by treatment of the culprit artery only in patients with acute myocardial infarction ...

MATRIX: Superioridad del acceso radial al año

ESC 2018 | MATRIX: 1-Year Superiority of Transradial Access
Transradial access should be the access of choice in patients with acute coronary syndrome, while bivalirudin has not shown any benefit for this population. The long-term follow-up from ...

FUTURE: una piedra en el zapato para el FFR y más preguntas que respuestas

ESC 2018 | FUTURE: A Thorn in FFR and More Questions than Answers
As observed at the preliminary analysis that motivated the FUTURE trial early termination, the use of fractional flow reserve (FFR) to guide revascularization in an unselected population with ...

GLOBAL LEADERS: El ticagrelor como monoterapia no supera a los esquemas clásicos post angioplastia

ESC 2018 | GLOBAL LEADERS: Ticagrelor Monotherapy Is Not Superior to Classic Therapies After Angioplasty
Dropping aspirin after the first month and continuing with ticagrelor monotherapy was not better than standard dual antiplatelet therapy (aspirin plus ticagrelor or clopidogrel) in patients who ...

ARRIVE: la aspirina en el ojo de la tormenta de la prevención primaria

ESC 2018 | ARRIVE: Aspirin in the Eye of the Storm of Primary Prevention
Aspirin failed to reach the primary endpoint in a population that was at risk of experiencing cardiovascular disease. However, something that a short time ago seemed obvious could not be proved by ...

CLARIFY: No hay beneficio en sobrevida con betabloqueantes más allá de un año post infarto

ESC 2018 | CLARIFY: No Survival Benefit with Beta-Blockers Beyond 1 Year After Infarction
This is another study that concludes that beta-blockers have no impact on mortality at 1 year after infarction in stable patients and offer no survival benefit to patients with stable ischemic ...

ASCEND: Aspirina para prevención primaria en diabéticos no pasa el costo/beneficio

ESC 2018 | ASCEND: Aspirin for Primary Prevention in Diabetic Patients Fails the Cost-Benefit Analysis
The obvious risk of bleeding posed by aspirin was too clear in this work, casting a shadow of doubt over the indication of aspirin for primary prevention in diabetic patients. According ...

MATRIX: Superioridad del acceso radial al año

ESC 2018 | MATRIX: 1-Year Superiority of Transradial Access
Transradial access should be the access of choice in patients with acute coronary syndrome, while bivalirudin has not shown any benefit for this population. The long-term follow-up from ...

MARINER: Rivaroxaban como trombo profilaxis luego de una hospitalización

ESC 2018 | MARINER: Rivaroxaban as Thromboprophylaxis after Hospitalization
For acute patients hospitalized for a clinical disease (e.g.: heart failure), indicating rivaroxaban for 6.5 weeks after discharge did not significantly reduce the risk of symptomatic venous ...

Top